Understand the source comparison
PEGylated Peptides Extended Half-Life Technology: Clinical Applications Comparison
GLP-1 agonists 2–3 minutes 13 hours (exenatide) None (exendin-4 analog) Exenatide (Byetta) Twice daily → once weekly (Bydureon, microsphere formulation) Growth hormone 20–30 minutes 33 hours 40 kDa branched PEG Pegvisomant (Somavert) Daily → weekly under devel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 agonists
- 2–3 minutes
- 13 hours (exenatide)
- None (exendin-4 analog)
- Exenatide (Byetta)
- Twice daily → once weekly (Bydureon, microsphere formulation)
- Growth hormone
- 20–30 minutes
- 33 hours
- 40 kDa branched PEG
- Pegvisomant (Somavert)
- Daily → weekly under development
- Interferon-alpha
- 4–6 hours
- 40 hours (PEG-IFNα-2a)
- Pegasys (hepatitis C)
- 3× weekly → once weekly
- Erythropoietin
- 8 hours
- 130 hours
- 30 kDa PEG
- Mircera (anemia)
- 3× weekly → once every 2 weeks
- GHRH analogs
- 7–10 minutes
- 48–72 hours
- 20 kDa linear PEG
- Tesamorelin (lipodystrophy)
- Twice daily → once daily
- This comparison shows that PEGylated peptides extended half-life technology consistently delivers 5–20× half-life extension across diverse peptide classes, translating to meaningful dosing convenience without requiring fundamentally different administration routes. The PEG size selected correlates with the native peptide's clearance rate. Rapidly cleared peptides (minutes) require larger PEG (30–40 kDa) to reach practical dosing intervals, while peptides with moderate native half-lives (hours) achieve sufficient extension with smaller PEG (5–20 kDa).